R&D | December 09, 2025
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Expanding US operations to address the increased demand for API development and manufacturing
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Subscribe To Our Newsletter & Stay Updated
